Results 211 to 220 of about 1,664,796 (355)

A database study of the safety and effectiveness of daily growth hormone in treating more than 80,000 children with growth disorders worldwide: a plain language summary of publication. [PDF]

Ther Adv Endocrinol Metab
Maghnie M, Ranke MB, Geffner ME, Vlachopapadopoulou E, Ibáñez L, Carlsson M, Cutfield W, Rooman R, Gomez R, Wajnrajch MP, Linglart A, Stawerska R, Clayton PE, Darendeliler F, Hokken-Koelega ACS, Horikawa R, Tanaka T, Dörr HG, Polak M, Grimberg A.   +19 more
europepmc   +1 more source

An eHealth Framework for Managing Pediatric Growth Disorders and Growth Hormone Therapy.

J Med Internet Res, 2021
Dimitri P, Fernandez-Luque L, Banerjee I, Bergadá I, Calliari LE, Dahlgren J, de Arriba A, Lapatto R, Reinehr T, Senniappan S, Thomas-Teinturier C, Tsai MC, Anuar Zaini A, Bagha M, Koledova E.   +14 more
europepmc   +1 more source

Age‐Related Characteristics of SYT1‐Associated Neurodevelopmental Disorder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives We describe the clinical manifestations and developmental abilities of individuals with SYT1‐associated neurodevelopmental disorder (Baker‐Gordon syndrome) from infancy to adulthood. We further describe the neuroradiological and electrophysiological characteristics of the condition at different ages, and explore the associations ...
Sam G. Norwitz, Josefine Eck, Joel S. Winston, Kate Baker   +3 more
wiley   +1 more source

The Treatment of Growth Disorders in Childhood and Adolescence. [PDF]

Dtsch Arztebl Int
Woelfle J, Schnabel D, Binder G.
europepmc   +1 more source

Predictors of Anxiety Symptom Trajectory in Children with or without ID from Early Childhood to Adolescence [PDF]

, 2020
Baker, Bruce L, Blacher, Jan, Rodas, Naomi V   +2 more
core   +1 more source

A multi-scale model for determining the effects of pathophysiology and metabolic disorders on tumor growth

, 2020
Mohammad R. Nikmaneshi, Aliasghar Mozafari, Lance L. Munn, Bahar Firoozabadi   +3 more
openalex   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Editorial: Challenges in pediatric endocrinology regarding alterations in glucose metabolism, growth disorders, disorders of sex development, and puberty in adolescents. [PDF]

Front Pediatr
Maltoni G, Candela E, Tornese G.
europepmc   +1 more source

Placental growth disorders and perinatal adverse outcomes in Brazilian HIV-infected pregnant women. [PDF]

PLoS One, 2020
Dos Reis HLB, Boldrini NAT, Rangel AFR, Barros VF, Merçon de Vargas PR, Miranda AE.   +5 more
europepmc   +1 more source